|
Match
|
Document |
Document Title |
|
|
US20080161300 |
Heterobicyclic metalloprotease inhibitors
The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More...
|
|
|
US20080113949 |
Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin II antagonist for stroke prevention
This invention relates to a method of preventing stroke or reducing the risk of stroke in a patient in need thereof, especially in a patient at risk for a stroke or a secondary stroke, using...
|
|
|
US20080113934 |
USE OF DIPYRIDAMOLE OR MOPIDAMOL FOR TREATMENT AND PREVENTION OF FIBRIN-DEPENDENT MICROCIRCULATION DISORDERS
A method of treatment of the human or non-human animal body for treating fibrin-dependent microcirculation disorders is disclosed, for example, microcirculation disorders caused by metabolic...
|
|
|
US20080113024 |
Methods and compositions for treating platelet-related disorders
Provided are prophylactic and therapeutic methods of treatment of subjects for the purpose of inhibiting vaso-occlusive events, including embolism, by administering agents, including anagrelide and...
|
|
|
US20080096868 |
1,4 Substituted Pyrazolopyrimidines as Kinase Inhibitors
The invention relates to 1,4-substituted pyrazolopyrimidine compounds of the formula I,
pharmaceuticals comprising a 1,4-substituted pyrazolopyrimidine compound, the use of a 1,4-substituted...
|
|
|
US20080090847 |
HETEROCYCLIC COMPOUNDS AND USES THEREOF AS D-ALANYL-D-ALANINE LIGASE INHIBITORS
The invention is based on the discovery of a new class of heterocyclic compounds having, for example, antibacterial properties. The D-Ala-D-Ala ligase enzyme is a critical pathway enzyme in the...
|
|
|
US20080076786 |
USE OF RADICAL-SCAVENGING COMPOUNDS FOR TREATMENT AND PREVENTION OF NO-DEPENDENT MICROCIRCULATION DISORDERS
A method of treatment of the human or non-human animal body for treating NO-dependent microcirculation disorders is disclosed, for example microcirculation disorders caused by metabolic diseases,...
|
|
|
US20080064654 |
METHODS, COMPOSITIONS, UNIT DOSAGE FORMS, AND KITS FOR PHARMACOLOGIC STRESS TESTING WITH REDUCED SIDE EFFECTS
Methods are presented that comprise the administration of a pharmaceutical composition comprising adenosine and dipyridamole, as well methods comprising the combined administration of dipyridamole...
|
|
|
US20080058319 |
FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS
Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More...
|
|
|
US20080051408 |
Use of a Pde 5 Inhibitor for Treating and Preventing Hypopigmentary Disorders
The invention relates to the use of PDE5 inhibitors, preferably sildenafil or tadalafil, optionally in combination with a further active ingredient, for treating and/or preventing hypopigmentary...
|
|
|
US20080045489 |
3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS
Disclosed are novel cyclobutenedione Compounds 1 to 18 comprising a cyclobutenedione ring, a substituted phenyl ring, and a —CH(C 2 H 5 )-furan moiety. The phenyl ring and the —CH(C 2 H 5...
|
|
|
US20080038242 |
Benzimidazole derivatives and medical uses thereof
The present invention provides benzimidazole derivatives represented by the following formula (I) or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exert an inhibitory...
|
|
|
US20080032971 |
8-HETEROARYLPURINE MNK2 INHIBITORS FOR TREATING METABOLIC DISORDERS
Compounds of the formula
are disclosed as Mnk2 inhibitors which are useful for the treatment and prevention of metabolic disorders such as obesity and diabetes.
|
|
|
US20080032970 |
Amide Derivatives of 7-Amino-3-Phenyl-Dihydropyrimido[4,5-D]Pyrimidinones, Their Manufacture and Use as Pharmaceutical Agents
The present invention relates to novel amide derivatives of 7-amino-3-phenyl dihydropyrimido[4,5-d]pyrimidinones, to a process for their manufacture, medicaments containing them and their...
|
|
|
US20080032933 |
Type V Phosphodiesterase Inhibitors and Natriuretic Polypeptides
This document provides methods and materials related to PDE V inhibitors, natriuretic polypeptides, and combinations thereof. For example, compositions containing one or more PDE V inhibitors in...
|
|
|
US20080031958 |
Composition for accelerating bone fracture healing
|
|
|
US20080027050 |
Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio)
The present invention provides a novel amide derivative having a matrix metalloproteinase inhibitory activity, and useful as a pharmaceutical agent, which is a compound represented by the formula...
|
|
|
US20080026077 |
METHODS AND COMPOSITIONS OF GENE DELIVERY AGENTS FOR SYSTEMIC AND LOCAL THERAPY
A method is provided for the delivery of a therapeutic to epithelial cells through the use of a bile acid conjugated to a peptide, the peptide being ionically charged at physiological pH. The...
|
|
|
US20080025965 |
Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein levels
The invention features methods and compositions for reducing the serum C-reactive protein (CRP) level in a patient in need thereof, and for treating diseases and conditions associated with an...
|
|
|
US20080021005 |
Pegylated Ion Channel Modulating Compounds
This invention is directed to PEGlyated derivatives, drug conjugates and isotopic derivatives of certain ion channel modulating compounds. Pharmaceutical compositions and methods of use of also...
|
|
|
US20080009498 |
Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use
The invention provides novel compositions containing at least one phosphodiesterase inhibitor, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels...
|
|
|
US20080009496 |
MUTAGENIC HETEROCYCLES
The present invention provides compounds as well as methods of using the compounds as antiviral and anti-cancer chemotherapeutic agents.
|
|
|
US20080003213 |
Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein, interleukin-6, or interferon-gamma levels
The invention features methods and compositions for reducing the serum C-reactive protein (CRP), IL-6, and/or IFN-γ levels in a patient in need thereof, and for treating diseases and conditions...
|